is a partner at Axinn, Veltrop & Harkrider LLP. Stacie’s practice focuses on intellectual property litigation, due diligence and client counseling, with an emphasis on the life sciences. Her IP counseling and due diligence experience includes extensive counseling for product development efforts relating to biologics and reconstructive biomaterials, including products that utilize adult stem cells. In addition, Stacie has served on the trial team for several patent lawsuits involving major pharmaceutical companies.
For more information or to contact Stacie, please visit her Firm Profile Page.
The University of California (“UC”) and The Broad Institute, Inc. (“Broad”) are among the leaders in the development of CRISPR technology. Both UC and Broad filed patent applications for claims broadly drawn to CRISPR-Cas9 systems and methods of DNA editing. These parties are currently engaged in litigation over patents concerning the potentially most lucrative application of CRISPR technology – the use of CRISPR-Cas9 in plant and animal (eukaryotic) cells. The outcome of this litigation will affect control of the CRISPR platform and development of the technology.